Veredus Laboratories Pte Ltd “Veredus” today announced the CE-IVD marking of VereCoV™ Detection Kit for commercial launch in Europe. The test is intended for the qualitative detection of 2019 novel Coronavirus (2019-nCoV) also known as SARSCoV- 2 that causes COVID-19.
The kit was developed to provide an easy-to-use solution for clinical testing, public health surveillance and detection of the coronavirus from nasal or nasopharyngeal swab specimen to enable authorities to take appropriate actions. The test integrates PCR amplification and microarray for rapid qualitative detection of 2019-nCoV with the additional capability to detect a subset of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) simultaneously with the same test.
“We are ready to respond effectively to the needs of hospitals and reference laboratories by providing a quality molecular testing solution for the pandemic,” says Dr Rosemary Tan, Chief Executive Officer of Veredus Laboratories.
In the light of recent developments related to the ongoing COVID-19
outbreak, Veredus Laboratories is supporting the bio-surveillance detection
efforts by swab tests from travellers at land, sea and air checkpoints in
Singapore. Using the VerePLEX™ Biosystem that utilises the Lab-on-Chip
technology, the VereCoV™ Detection Kit is used for the multiplexed screening
and detection of the viral nucleic acid.
For more information on the additional precautionary
measures in response to the global situation of escalating COVID-19 infection, please
refer to the Ministry of Health
Singapore website at https://www.moh.gov.sg/news-highlights/details/additional-precautionary-measures-in-response-to-escalating-global-situation
to find out more.
Learn more about the swab test that has been implemented at
Singapore checkpoints beginning 4March 2020 at http://bit.ly/2vEfKmb .
Veredus Laboratories Pte Ltd “Veredus” has obtained the Provisional Authorisation from Singapore Health Sciences Authority (HSA) for its VereCoV™ Detection Kit following Veredus’ rapid launch of this kit as a “Research Use Only” (RUO) test earlier this year. With this Authorisation, VereCoV™ Detection Kit can be used directly by laboratories or hospitals to test patients for clinical diagnosis.
Veredus Laboratories Pte Ltd “Veredus”, a leading provider of innovative molecular diagnostic solutions, announced today the development of VereCoV detection kit, a portable Lab-on-Chip application capable of detecting the Middle-East Respiratory Syndrome Coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and 2019 Novel Coronavirus (2019-nCoV) i.e. Wuhan Coronavirus, in a single test.
Look for us at Booth 38 during the 8th edition of Europe’s highly successful Non-Conventional Threat: CBRNe Europe 2019 that will take place 25-27 July 2019 in Intercontinental Hotel in Vienna, Austria. The three-day event will feature live CBRNe capability demonstrations, one conference stream, multiple workshops, training sessions for civil and military responders, a large indoor and outdoor industry exhibition.
Click here to read more
Dear Veredus Customers,
We are pleased to unveil our new company logo as part of synergy efforts between Veredus and our parent company SEKISUI CHEMICAL CO. LTD.
SEKISUI-Veredus will maintain “Veredus Laboratories” as a product logo on its product line. The registered company name will remain as “Veredus Laboratories Pte Ltd”.
For more information, please refer to the notification attached.
VereBeef™ Detection Kit used in conjunction with the VerePLEX™ Biosystem is best described as an integration of both multiplex PCR and microarray on a Lab-on-Chip platform (VereChip™). It was specifically developed for the qualitative detection and differentiation of Escherichia coli (E. coli) O157:H7, E. coli O26, E. coli O45, E. coli O103, E. coli O111, E. coli O121, E. coli O145, STEC virulence factors (stx1A, stx2A, eae), and Salmonella spp. in a single test using raw beef trim samples.
VereBeef Press Release Final (Singapore)
Veredus Laboratories Pte Ltd is pleased to announce its acquisition by SEKISUI CHEMICAL CO., LTD1.
Founded in 2003, Veredus Laboratories Pte Ltd (hereinafter, “Veredus”) specializes in the development, manufacturing and marketing of innovative multiplexed molecular solutions in the clinical, specialty, and custom testing markets based on STMicroelectronics’ Lab-on-Chip platform. The Lab-on-Chip platform, also known as the VerePLEX™ Biosystem, combines Micro-Electro Mechanical Systems (MEMS) with micro-fluidics to integrate multiplexed DNA amplification with microarray detection for rapid, cost-effective, and accurate analysis of biological materials.
With this acquisition, Veredus will continue to carry its own product line and also welcome the medical products from SEKISUI MEDICAL CO., LTD., a company which is 100% subsidiary of SEKISUI CHEMICAL CO., LTD.
Dr Rosemary Tan will continue to lead Veredus as its Chief Executive Officer, and Veredus remains fully committed in bringing innovative technologies and quality products to our customers.
1Refer to Official Press Release by SEKISUI CHEMICAL CO., LTD, dated 3rd April, 2018
VereFever™ is able to detect, differentiate and identify 7 different major tropical diseases from a single blood sample, including Malaria, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis and Zika by using the STMicroelectronics proprietary Lab-on-Chip platform that integrates two powerful molecular biological applications, Polymerase Chain Reaction (PCR) and a microarray.